Cross‐Sex Hormone Therapy Alters the Serum Lipid Profile: A Retrospective Cohort Study in 169 Transsexuals

2011 ◽  
Vol 8 (8) ◽  
pp. 2361-2369 ◽  
Author(s):  
Johannes Ott ◽  
Stefanie Aust ◽  
Regina Promberger ◽  
Johannes C. Huber ◽  
Ulrike Kaufmann
2011 ◽  
Vol 8 (2) ◽  
pp. 125-133
Author(s):  
A Yasemin Karageyim Karsidag ◽  
Nevriye Alkan ◽  
Esra Esim Buyukbayrak ◽  
Bulent Kars ◽  
Meltem Pirimoglu ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Sherif Eltonsy ◽  
Monique Dufour Doiron ◽  
Patrice Simard ◽  
Caroline Jose ◽  
Martin Sénéchal ◽  
...  

Background. Statins and exercise are recommended for managing hypercholesterolemia. However, statin types may vary in their interaction with exercise. We compared rosuvastatin versus atorvastatin combination with exercise on lipid profile and functional capacity. Methods. A retrospective cohort study using data from a 12-week cardiovascular rehabilitation program between 2014 and 2016. Statin use was determined through prescriptions, and the average exercise minutes/week were computed from exercise logs. The outcomes were changes in total cholesterol, low- and high-density lipoproteins (LDL and HDL), triglycerides, and functional capacity (6-minute walk test (6MWT)). Directed acyclic graphs were used to identify potential confounders, accounted for using multiple linear regression modeling. Results. The cohort included 282 patients from 106 atorvastatin and 176 rosuvastatin users. The average exercise minutes/week was 109.4±66.1 among atorvastatin and 106.7±49.1 among rosuvastatin users. Interaction models suggested that a higher number of exercise minutes/week were more favorable among atorvastatin users on total cholesterol and LDL (0.004, 95% CI: 0.001, 0.008 and 0.004, 95% CI: 0.001, 0.007, respectively) but did not reach significance for HDL and triglycerides. Rosuvastatin use was associated with greater increases in 6MWT; however, we observed no between-group differences in interaction estimates by the type of statin used. Conclusion. Rosuvastatin use could blunt the beneficial effect of exercise on LDL and total cholesterol compared to atorvastatin. No significant differences were observed in triglycerides, HDL, and functional capacity levels. Additional studies are warranted with randomized treatments and larger samples. Healthcare providers should continue prescribing statins alongside recommending exercise modalities, with a careful follow-up for rosuvastatin users.


2003 ◽  
Vol 13 (2) ◽  
pp. 63-71 ◽  
Author(s):  
Akizumi Tsutsumi ◽  
Kazunori Kayaba ◽  
Shizukiyo Ishikawa ◽  
Tadao Gotoh ◽  
Naoki Nago ◽  
...  

2016 ◽  
Vol 35 (1) ◽  
pp. 73-81 ◽  
Author(s):  
Nabih I. El Khouly ◽  
Zakaria F. Sanad ◽  
Said A. Saleh ◽  
Ayman A. Shabana ◽  
Alaa F. Elhalaby ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Toka Alsulaim ◽  
Noor Alhassan ◽  
Hala Khalil ◽  
Abdullah Almutlaq

Objective. To study the effect of tocilizumab initiation on the lipid profile, in correlation to a composite of any cardiovascular events. Methods. A retrospective cohort study, using data from the King Faisal Specialist Hospital & Research Centre database, from January 2014 to December 2019. Patients with rheumatoid arthritis or juvenile idiopathic arthritis who were ≥18 years old, initiated either on tocilizumab or other biologic treatment (anti-TNFs or Rituximab), were included, with a follow-up interval duration at a minimum of 6–12 months up to 3-5 years. Any patient with established cardiovascular disease or aged <18 were excluded. Results. Only one cardiovascular mortality was reported in the tocilizumab group. Fifty percent of patients reached high   cholesterol   levels ≥ 5.2   mmol / L and LDL ≥ 3.37   mmol / L in the tocilizumab group at 36 months in a shorter time period compared to controls (60 months), P  0.001. There were no significant differences between groups for statin use (27% vs. 28%) However, there was a significantly higher mean dose of atorvastatin in the tocilizumab group compared to controls (20.6 mg vs. 16.6 mg, P  0.03). Conclusion. There was a lack of evidence of increased cardiovascular risk in correlation to hyperlipidemia secondary to tocilizumab treatment.


Sign in / Sign up

Export Citation Format

Share Document